home / stock / cere / cere quote
Last: | $42.63 |
---|---|
Change Percent: | -0.05% |
Open: | $42.73 |
Close: | $42.63 |
High: | $42.86 |
Low: | $42.6 |
Volume: | 931,485 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$42.63 | $42.73 | $42.63 | $42.86 | $42.6 | 931,485 | 05-01-2024 |
$42.71 | $42.57 | $42.71 | $42.82 | $42.56 | 1,059,658 | 04-30-2024 |
$42.75 | $42.49 | $42.75 | $42.845 | $42.38 | 714,167 | 04-29-2024 |
$42.47 | $42.02 | $42.47 | $42.491 | $41.93 | 680,906 | 04-26-2024 |
$42.07 | $41.81 | $42.07 | $42.185 | $41.8 | 691,659 | 04-25-2024 |
$41.9 | $41.97 | $41.9 | $42.06 | $41.87 | 629,646 | 04-24-2024 |
$41.99 | $42.1 | $41.99 | $42.14 | $41.9 | 1,389,982 | 04-23-2024 |
$42.1 | $42.28 | $42.1 | $42.3 | $41.86 | 701,473 | 04-22-2024 |
$42.21 | $42.01 | $42.21 | $42.23 | $42 | 813,324 | 04-19-2024 |
$42.14 | $41.88 | $42.14 | $42.21 | $41.7 | 1,282,830 | 04-18-2024 |
$41.6 | $41.47 | $41.6 | $41.8 | $41.3 | 838,023 | 04-17-2024 |
$41.31 | $41.6 | $41.31 | $41.805 | $41.185 | 1,439,526 | 04-16-2024 |
$41.7 | $41.83 | $41.7 | $41.92 | $41.535 | 1,333,538 | 04-15-2024 |
$41.85 | $42.02 | $41.85 | $42.045 | $41.5 | 2,259,340 | 04-12-2024 |
$42.01 | $42.17 | $42.01 | $42.18 | $42 | 948,569 | 04-11-2024 |
$42.11 | $42.1 | $42.11 | $42.2706 | $42.04 | 1,218,905 | 04-10-2024 |
$42.13 | $42.2 | $42.13 | $42.2 | $42.035 | 748,979 | 04-09-2024 |
$42.21 | $42.17 | $42.21 | $42.28 | $42.1 | 1,057,738 | 04-08-2024 |
$42.17 | $42.15 | $42.17 | $42.28 | $42.04 | 976,840 | 04-05-2024 |
$42.17 | $42.31 | $42.17 | $42.405 | $42.155 | 1,386,066 | 04-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapad...
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to ...